Key result
Prolonged treatment of alveolar monolayers with K+ channel inhibitors reduced ENaC and CFTR expression and fluid absorption, whereas the K+ channel activator pinacidil increased them.
Long-term regulation of ENaC and CFTR expression by K+ channel activity modulates alveolar fluid transport, suggesting a potential therapeutic target for pulmonary diseases affecting fluid clearance.
K+ channel modulation may alter alveolar fluid clearance; animal data leaves open therapeutic targeting in human pulmonary edema.
In a recent study (Leroy C, Dagenais A, Berthiaume Y, and Brochiero E. Am J Physiol Lung Cell Mol Physiol 286: L1027-L1037, 2004), we identified an ATP-sensitive K(+) (K(ATP)) channel in alveolar epithelial cells, formed by inwardly rectifying K(+) channel Kir6.1/sulfonylurea receptor (SUR)2B subunits. We found that short applications of K(ATP), voltage-dependent K(+) channel KvLQT1, and calcium-activated K(+) (K(Ca)) channel modulators modified Na(+) and Cl(-) currents in alveolar monolayers. In addition, it was shown previously that a K(ATP) opener increased alveolar liquid clearance in human lungs by a mechanism possibly related to epithelial sodium channels (ENaC). We therefore hypothesized that prolonged treatment with K(+) channel modulators could induce a sustained regulation of ENaC activity and/or expression. Alveolar monolayers were treated for 24 h with inhibitors of K(ATP), KvLQT1, and K(Ca) channels identified by PCR. Glibenclamide and clofilium (K(ATP) and KvLQT1 inhibitors) strongly reduced basal transepithelial current, amiloride-sensitive Na(+) current, and forskolin-activated Cl(-) currents, whereas pinacidil, a K(ATP) activator, increased them. Interestingly, K(+) inhibitors or membrane depolarization (induced by valinomycin in high-K(+) medium) decreased alpha-, beta-, and gamma-ENaC and CFTR mRNA. alpha-ENaC and CFTR proteins also declined after glibenclamide or clofilium treatment. Conversely, pinacidil augmented ENaC and CFTR mRNAs and proteins. Since alveolar fluid transport was found to be driven, at least in part, by Na(+) transport through ENaC, we tested the impact of K(+) channel modulators on fluid absorption across alveolar monolayers. We found that glibenclamide and clofilium reduced fluid absorption to a level similar to that seen in the presence of amiloride, whereas pinacidil slightly enhanced it. Long-term regulation of ENaC and CFTR expression by K(+) channel activity could benefit patients with pulmonary diseases affecting ion transport and fluid clearance.
No takes yet. Share an insight, caveat, or question.
Leroy et al. (2006) studied Pulmonary diseases affecting ion transport. K+ channel modulators (glibenclamide, clofilium, pinacidil) vs. Basal/untreated was evaluated on ENaC and CFTR expression and fluid absorption across alveolar monolayers. Prolonged treatment of alveolar monolayers with K+ channel inhibitors reduced ENaC and CFTR expression and fluid absorption, whereas the K+ channel activator pinacidil increased them.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: